Clinical Trial Update: Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) [Phase 2]

View source ↗

Summary

Phase 2 GALAXY 3 trial assessing neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Lung Cancer - Non Small Cell | Phase 2 | Status: RECRUITING